Elixinol Wellness (ASX:EXL) EBITDA Margin %: -31.14% (As of Dec. 2025)


What is Elixinol Wellness EBITDA Margin %?

Elixinol Wellness ASX:EXL EBITDA Margin % is -31.14% as of Dec. 2025. The stock has 7 warning signs investors should review. Among 955 Drug Manufacturers companies, Elixinol Wellness ranks worse than 86.49% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Elixinol Wellness's EBITDA for the six months ended in Dec. 2025 was A$-2.45 Mil. Elixinol Wellness's Revenue for the six months ended in Dec. 2025 was A$7.86 Mil. Therefore, Elixinol Wellness's EBITDA margin for the quarter that ended in Dec. 2025 was -31.14%.

Elixinol Wellness  (ASX:EXL) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Elixinol Wellness EBITDA Margin % Related Terms

Elixinol Wellness EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Elixinol Wellness's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elixinol Wellness EBITDA Margin % Chart

Elixinol Wellness Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial -151.20 -131.55 -82.31 -27.36 -30.65

Elixinol Wellness Semi-Annual Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -76.94 -31.78 -23.70 -30.14 -31.14

ASX:EXL vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Elixinol Wellness's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Elixinol Wellness EBITDA Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Elixinol Wellness's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Elixinol Wellness's EBITDA Margin % falls into.


Elixinol Wellness EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Elixinol Wellness's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-4.75/15.5
=-30.65 %

Elixinol Wellness's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-2.447/7.858
=-31.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -31.14% mean?
Elixinol Wellness (ASX:EXL) has a EBITDA Margin % of -31.14% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Elixinol Wellness and its competitors. According to the industry distribution chart, Elixinol Wellness ranks #826 out of 955 companies in the Drug Manufacturers industry, placing it in the top 86.5%.
Is Elixinol Wellness' EBITDA Margin % too high?
Elixinol Wellness' current EBITDA Margin % is -31.14%. Based on the distribution chart, Elixinol Wellness ranks #826 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Elixinol Wellness' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Elixinol Wellness ranks #826 out of 955 companies for EBITDA Margin %. This places Elixinol Wellness in the lower half of its industry. The industry median EBITDA Margin % is 12.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Elixinol Wellness and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elixinol Wellness's current EBITDA Margin % is -31.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elixinol Wellness stock overvalued right now?
Based on GuruFocus' analysis, Elixinol Wellness (ASX:EXL) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.01 — trading 70% below its estimated fair value. The current EBITDA Margin % is -31.14%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Elixinol Wellness (ASX:EXL), the current EBITDA Margin % is -31.14% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Elixinol Wellness Business Description

Other Exchanges ELLXF:USAE8M:Germany
Address 51 - 53 Riversdale Road, Newtown, VIC, AUS, 3220
Elixinol Wellness Ltd is engaged in the hemp industry, innovating, marketing, and selling hemp-derived nutraceutical, cosmetic, and food products. It operates in the three operating segments of the Americas, Australia, Rest of the World regions of which key revenue is derived from the Australia segment. The Australia segment includes the results from operations of Elixinol Wellness (Byron Bay) Pty Ltd and The Sustainable Nutrition Group Pty Ltd and its subsidiaries. It derives maximum revenue from Australia.